IMVT
Immunovant, Inc.
$31.61
+2.63%
$6.3B
No data for this timeframe.
Vol
Market Cap$6.3B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders6 funds
Inst. Value$779.2M
Inst. Activity2 buys / 0 sells
Insider Activity0B / 12S
Insider Net $-$2.5M
SEC Reports5
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001764013·Prev Close $30.80
Recent Activity
Jun 5, 2026
SEC
Director Andrew J. Fromkin filed a Form 144 on May 28, 2026, indicating intent to sell up to 221,951 shares of Immunovan
144 — Impact 3/10
Jun 2, 2026
short_volume
Short Volume: IMVT — 60.5% short (0.4M / 0.7M)
Short: 429,761 | Exempt: 2,668 | TRF Vol: 710,699 | Short Ratio: 60.5% | Off-exchange volume (dark p
May 28, 2026
Insider
Fromkin Andrew J. sold 11,483 shares
Director @ $32.64 ($374.8K)
May 28, 2026
Insider
Fromkin Andrew J. sold 31,668 shares
Director @ $4.99 ($158.0K)
May 28, 2026
Insider
Fromkin Andrew J. sold 31,668 shares
Director @ $0.00 ($0.00)
May 20, 2026
SEC
Immunovant reported fiscal Q4 2026 results with a net loss of $147.9M ($0.73/share), wider than the $106.4M loss a year
8-K — Impact 6/10
May 20, 2026
SEC
Immunovant reported Q4 FY2026 net loss of $0.73/share, wider than prior year's $0.64 loss, driven by increased R&D spend
PRESS-RELEASE — Impact 7/10
Inst.
MORGAN STANLEY — DOUBLED
4,846,385 shares ($123.2M)
Price Targets
$45.76
+44.8% upside
Strong Buy
Current $31.61
Low $24.00
Median $45.00
High $66.00
17 analysts
$24.00
$66.00
Analyst Ratings
9Strong Buy
9Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| May 22, 2026 | Truist Securities | MAINTAIN | Hold → Hold |
| May 21, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| May 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 15, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.48 ▲ +47.9% | $-0.48 — $-0.48 | 33% YoY | 1 |
| Next Q | $-0.53 ▲ +45.2% | $-0.53 — $-0.53 | 19% YoY | 1 |
| Current FY | $-2.44 ▲ +5.4% | $-2.94 — $-1.75 | 1% YoY | 4 |
| Next FY | $-2.44 ▼ -2.3% | $-3.61 — $-1.24 | 0% YoY | 4 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $431.9M | ADD |
| VANGUARD GROUP INC | $197.8M | — |
| MORGAN STANLEY | $123.2M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $16.3M | NEW |
| BANK OF AMERICA CORP | $8.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | Fromkin Andrew | SELL | $374.8K |
| May 28, 2026 | Fromkin Andrew | M | $158.0K |
| May 28, 2026 | Fromkin Andrew | M | $0.00 |
| May 20, 2026 | Pande Atul | M | $0.00 |
| May 20, 2026 | Pande Atul | M | $50.6K |
6 institutional holders with $779.2M total value (30,652,575 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 16,990,754 | $431.9M | 55.4% | ADD +31.6% |
| 2 | VANGUARD GROUP INC | 7,779,314 | $197.8M | 25.4% | — |
| 3 | MORGAN STANLEY | 4,846,385 | $123.2M | 15.8% | DOUBLED +147.4% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 642,974 | $16.3M | 2.1% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 313,481 | $8.0M | 1.0% | — |
| 6 | WELLS FARGO & COMPANY/MN | 79,667 | $2.0M | 0.3% | ADD +77.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 1,959,026 | 4,846,385 | +147.4% | $123.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 44,937 | 79,667 | +77.3% | $2.0M | 2025-Q4 |
| NORGES BANK | EXIT | 687,662 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 241,400 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 1,310,050 | 2,309,061 | +76.3% | $36.9M | 2025-Q2 |
| NORGES BANK | NEW | — | 687,662 | — | $11.0M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 395,900 | 241,400 | -39.0% | $3.9M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 28,793 | 36,273 | +26.0% | $580.4K | 2025-Q2 |
| FMR LLC | ADD | 13,097,915 | 17,241,035 | +31.6% | $294.6M | 2025-Q1 |
| MORGAN STANLEY | ADD | 1,010,624 | 1,310,050 | +29.6% | $22.4M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 80,900 | 395,900 | +389.4% | $6.8M | 2025-Q1 |
| NORGES BANK | EXIT | 637,947 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 524,321 | 719,413 | +37.2% | $17.8M | 2024-Q4 |
| UBS Group AG | DOUBLED | 164,989 | 614,764 | +272.6% | $15.2M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 189,000 | 80,900 | -57.2% | $2.0M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 18,714 | 28,063 | +50.0% | $695.1K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 552,430 | — | $15.7M | 2024-Q3 |
11 unique insiders with 12 transactions. Net insider value: -$2.5M ($0.00 bought, $2.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | Fromkin Andrew J. | Director | SELL | 11,483 | $32.64 | $374.8K |
| May 28, 2026 | Fromkin Andrew J. | Director | M | 31,668 | $4.99 | $158.0K |
| May 28, 2026 | Fromkin Andrew J. | Director | M | 31,668 | $0.00 | $0.00 |
| May 20, 2026 | Pande Atul | Director | M | 6,000 | $0.00 | $0.00 |
| May 20, 2026 | Pande Atul | Director | M | 6,000 | $8.43 | $50.6K |
| May 20, 2026 | Pande Atul | Director | SELL | 6,000 | $32.00 | $192.0K |
| May 20, 2026 | Gloria Melanie | Chief Operating Officer | SELL | 249 | $30.41 | $7.6K |
| May 1, 2026 | Susman Robert Graham | Director | SELL | 2,502 | $27.17 | $68.0K |
| Apr 23, 2026 | Stout Jay S | Chief Technology Officer | SELL | 2,754 | $29.62 | $81.6K |
| Apr 23, 2026 | Girao Tiago | Chief Financial Officer | SELL | 25,760 | $29.62 | $763.0K |
| Apr 8, 2026 | Stout Jay S | Chief Technology Officer | SELL | 8,614 | $24.83 | $213.9K |
| Apr 8, 2026 | Van Tuyl Christopher | Chief Legal Officer | SELL | 5,165 | $24.83 | $128.2K |
| Apr 8, 2026 | Gloria Melanie | Chief Operating Officer | SELL | 8,722 | $24.83 | $216.6K |
| Apr 7, 2026 | Girao Tiago | Chief Financial Officer | A | 64,968 | $0.00 | $0.00 |
| Apr 7, 2026 | Girao Tiago | Chief Financial Officer | A | 94,002 | $0.00 | $0.00 |
| Apr 7, 2026 | Venker Eric | Chief Executive Officer | A | 232,252 | $0.00 | $0.00 |
| Apr 7, 2026 | Venker Eric | Chief Executive Officer | A | 336,043 | $0.00 | $0.00 |
| Apr 7, 2026 | Van Tuyl Christopher | Chief Legal Officer | A | 41,343 | $0.00 | $0.00 |
| Apr 7, 2026 | Van Tuyl Christopher | Chief Legal Officer | A | 59,820 | $0.00 | $0.00 |
| Apr 7, 2026 | Stout Jay S | Chief Technology Officer | A | 66,937 | $0.00 | $0.00 |
| Apr 7, 2026 | Stout Jay S | Chief Technology Officer | A | 96,851 | $0.00 | $0.00 |
| Apr 7, 2026 | Gloria Melanie | Chief Operating Officer | A | 83,671 | $0.00 | $0.00 |
| Apr 7, 2026 | Gloria Melanie | Chief Operating Officer | A | 121,063 | $0.00 | $0.00 |
| Apr 7, 2026 | Susman Robert Graham | Director | A | 13,880 | $0.00 | $0.00 |
| Apr 7, 2026 | Susman Robert Graham | Director | A | 7,061 | $0.00 | $0.00 |
| Apr 7, 2026 | Bauer Jake | Director | A | 13,880 | $0.00 | $0.00 |
| Apr 7, 2026 | Bauer Jake | Director | A | 7,061 | $0.00 | $0.00 |
| Apr 7, 2026 | Hughes Douglas J. | Director | A | 13,880 | $0.00 | $0.00 |
| Apr 7, 2026 | Pande Atul | Director | A | 13,880 | $0.00 | $0.00 |
| Apr 7, 2026 | Pande Atul | Director | A | 7,061 | $0.00 | $0.00 |
| Apr 7, 2026 | Hughes Douglas J. | Director | A | 7,061 | $0.00 | $0.00 |
| Apr 7, 2026 | Fromkin Andrew J. | Director | A | 13,880 | $0.00 | $0.00 |
| Apr 7, 2026 | Torti Frank | Director | A | 174,189 | $0.00 | $0.00 |
| Apr 7, 2026 | Fromkin Andrew J. | Director | A | 7,061 | $0.00 | $0.00 |
| Apr 7, 2026 | Torti Frank | Director | A | 88,325 | $0.00 | $0.00 |
| Apr 2, 2026 | Venker Eric | Chief Executive Officer | SELL | 12,820 | $24.04 | $308.2K |
| Apr 1, 2026 | Venker Eric | Chief Executive Officer | D | 334,960 | $25.10 | $8.4M |
| Apr 1, 2026 | Venker Eric | Chief Executive Officer | M | 368,750 | $14.46 | $5.3M |
| Apr 1, 2026 | Venker Eric | Chief Executive Officer | M | 368,750 | $0.00 | $0.00 |
| Mar 18, 2026 | Van Tuyl Christopher | Chief Legal Officer | SELL | 2,877 | $24.97 | $71.8K |
| Feb 25, 2026 | Gloria Melanie | Chief Operating Officer | SELL | 1,437 | $26.98 | $38.8K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 4.4/10.
NEUTRAL
144
3/10
Director Andrew J. Fromkin filed a Form 144 on May 28, 2026, indicating intent to sell up to 221,951
Jun 5, 2026
MIXED
8-K
6/10
Immunovant reported fiscal Q4 2026 results with a net loss of $147.9M ($0.73/share), wider than the
May 20, 2026
BULLISH
PRESS-RELEASE
7/10
Immunovant reported Q4 FY2026 net loss of $0.73/share, wider than prior year's $0.64 loss, driven by
May 20, 2026
NEUTRAL
CLUSTER
3/10
Two C-suite executives at Immunovant — the CFO and CTO — sold shares worth $845,000 in open-market t
Apr 24, 2026
NEUTRAL
CLUSTER
3/10
Two Immunovant executives sold shares in open-market transactions totaling $522K, while multiple ins
Apr 10, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (75% buy). Based on 24 analysts: 9 strong buy, 9 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$45.76 mean target
+44.8% upside
Strong Buy (1.67)
$24.00 Low
$66.00 High
| Metric | Value |
|---|---|
| Current Price | $31.61 |
| Target Low | $24.00 |
| Target Mean | $45.76 |
| Target Median | $45.00 |
| Target High | $66.00 |
| # Analysts | 17 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.48 | $-0.48 | $-0.48 | 32.5% | +47.9% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.53 | $-0.53 | $-0.53 | 18.9% | +45.2% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2027-03-31 |
$-2.44 | $-2.94 | $-1.75 | 0.9% | +5.4% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
| Next FY 2028-03-31 |
$-2.44 | $-3.61 | $-1.24 | 0.3% | -2.3% | 1↑ 0↓ | $0.1B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.479 | |
| 7d ago | $0.000 | -0.479 |
| 30d ago | $-0.920 | +0.441 |
| 60d ago | $-0.810 | +0.331 |
| 90d ago | $-0.810 | +0.331 |
6 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 22, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| May 21, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| May 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 15, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 9, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Jan 6, 2026 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Dec 15, 2025 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 9 | 6 | 0 | 0 | 75% | |
| May 1, 2026 | 9 | 9 | 6 | 0 | 0 | 75% | |
| Apr 1, 2026 | 9 | 9 | 6 | 0 | 0 | 75% | |
| Mar 1, 2026 | 9 | 9 | 5 | 0 | 0 | 78% | |
| Feb 1, 2026 | 9 | 9 | 5 | 0 | 0 | 78% | |
| Jan 1, 2026 | 8 | 9 | 6 | 0 | 0 | 74% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
short_volume
Short Volume: IMVT — 60.5% short (0.4M / 0.7M)
Short: 429,761 | Exempt: 2,668 | TRF Vol: 710,699 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: IMVT — 57.0% short (0.4M / 0.8M)
Short: 432,710 | Exempt: 12,357 | TRF Vol: 759,735 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: IMVT — 59.5% short (0.5M / 0.8M)
Short: 463,206 | Exempt: 19,516 | TRF Vol: 777,918 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
May 20, 2026
earnings
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
<p>DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- <strong>Immunovant, Inc. (Nasdaq: IMVT)</strong>, a clinical-stage immunology company dedicated to
May 20, 2026
earnings_calendar
IMVT Q4 2026 Earnings After Market Close — 2026-05-20
May 19, 2026
short_volume
Short Volume: IMVT — 71.9% short (0.4M / 0.6M)
Short: 407,741 | Exempt: 9,135 | TRF Vol: 567,059 | Short Ratio: 71.9% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: IMVT — 58.3% short (0.5M / 0.9M)
Short: 524,807 | Exempt: 1,091 | TRF Vol: 900,325 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: IMVT — 63.7% short (0.3M / 0.5M)
Short: 323,780 | Exempt: 0 | TRF Vol: 508,593 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: IMVT — 55.6% short (0.4M / 0.7M)
Short: 408,450 | Exempt: 230 | TRF Vol: 734,485 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 1, 2026
Clinical Trial
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Phase Phase 3 — COMPLETED
May 1, 2026
clinical_trial_readout
Results Pending: Batoclimab (Phase 3) — Completed 87d ago
Trial: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Sponsor: Immunovant Sciences GmbH
Phase: Phase 3 | Completed: 2026-0
Apr 29, 2026
Clinical Trial
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
Phase Phase 3 — TERMINATED
Apr 29, 2026
short_volume
Short Volume: IMVT — 74.2% short (0.4M / 0.5M)
Short: 404,416 | Exempt: 134 | TRF Vol: 545,063 | Short Ratio: 74.2% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: IMVT — 66.2% short (0.6M / 0.9M)
Short: 604,176 | Exempt: 95 | TRF Vol: 912,344 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: IMVT — 67.2% short (0.4M / 0.6M)
Short: 381,936 | Exempt: 0 | TRF Vol: 568,705 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
short_volume
Short Volume: IMVT — 82.5% short (0.4M / 0.5M)
Short: 420,805 | Exempt: 2,552 | TRF Vol: 510,309 | Short Ratio: 82.5% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: IMVT — 64.9% short (0.6M / 0.9M)
Short: 588,269 | Exempt: 7,131 | TRF Vol: 905,983 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)